Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AVE 0847

Drug Profile

AVE 0847

Alternative Names: AVE0847

Latest Information Update: 07 Apr 2008

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genfit; sanofi-aventis
  • Developer sanofi-aventis
  • Class Antihyperglycaemics
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Lipid metabolism disorders; Type 2 diabetes mellitus

Most Recent Events

  • 04 Apr 2008 Discontinued - Phase-II for Lipid metabolism disorders in France (unspecified route)
  • 04 Apr 2008 Discontinued - Phase-II for Type-2 diabetes mellitus in France (unspecified route)
  • 01 Mar 2005 Phase-I clinical trials in Lipid metabolism disorders in France (unspecified route)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top